ASX Release

4 November 2026

CORRECTION TO PREVIOUS ANNOUNCEMENT RELATED TO CEO APPOINTMENT

The previously lodged announcement stated the appointment of Nicole Van Der Weerden as Acting Chief Executive Officer effective today. The Company corrects this statement confirming that Nicole Van Der Weerden has been appointed as Chief Executive Officer effective today.

Release authorised by the Arovella Limited Chair.

FURTHER INFORMATION

Dr Nicole Van Der Weerden
Chief Executive Officer
E nvanderweerden@arovella.com
M +61 407 039 983

David Williams
Chairman
E dwilliams@kidder.com.au
M + 61 414 383 593

About Arovella Therapeutics Ltd

Arovella Therapeutics Ltd (ASX: ALA) is focused on developing its invariant natural killer T (iNKT) cell therapy platform licensed from Imperial College London to treat blood cancers, solid tumours, and autoimmune disease. Arovella's lead product is ALA-101. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. iNKT cells also contain an invariant T cell receptor (iTCR) that targets glycolipid bound CD1d, another antigen found on the surface of several cancer types. ALA-101 has had its Investigational New Drug application (IND) accepted by the US FDA and is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. Arovella is also expanding into solid tumour treatment through its CLDN18.2-targeting technology licensed from Sparx Group. Arovella will also incorporate its IL-12-TM technology into its solid tumour programs.

For more information, visit www.arovella.com